The Pediatric Cardiology pharmacopoeia: 2004 update

被引:13
作者
Barnes, S
Shields, B
Bonney, W
Hardin, J
Abdulla, R
机构
[1] Univ Chicago, Dept Pediat, Chicago, IL 60637 USA
[2] Rush Med Coll, Dept Pediat & Anesthesiol, Chicago, IL 60612 USA
[3] Rush Med Coll, Dept Pharmacol, Chicago, IL 60612 USA
[4] Rush Med Coll, Dept Pediat, Chicago, IL 60612 USA
关键词
medications; pediatric; congenital heart disease; inotropes; antiarrhythmic; vasodilators; diuretics; sedatives; analgesics; subacute bacterial endocarditis prophylaxis; inhalation pulmonary vasodilators;
D O I
10.1007/s00246-003-0692-z
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Seven years ago, Pediatric Cardiology published the first version of a review article outlining the various medications used in the field of heart diseases in children. This article is an update and expansion to what we have previously presented. Therapeutic intervention, both surgical and through cardiac catheterization, has enabled cure and palliation of an increasingly expanding spectrum of diseases at earlier ages and with more complex lesions. Refinement of these procedures includes more advanced tools as well as the support of an expanding armament of pharmacopoeia used to stabilize and support patients before, during, and after such procedures. In addition to updating previously published data regarding inotropes, antiarrhythmics, vasodilators, diuretics, sedatives, and analgesics as well as a variety of miscellaneous medications, this article describes the use of pulmonary medications frequently needed in patients with congestive heart failure, pulmonary edema, and chronic lung disease. We also describe the difficult management of withdrawal as a result of use of sedatives and analgesics. The most recent recommendation for subacute bacterial endocarditis prophylactic antibiotic regimens is also described.
引用
收藏
页码:623 / 646
页数:24
相关论文
共 25 条
[1]   The pediatric cardiology pharmacopoeia [J].
Abdulla, R ;
Young, S ;
Barnes, SD .
PEDIATRIC CARDIOLOGY, 1997, 18 (03) :162-183
[2]   Vasodilator therapy for primary pulmonary hypertension in children [J].
Barst, RJ ;
Maislin, G ;
Fishman, AP .
CIRCULATION, 1999, 99 (09) :1197-1208
[3]   A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension [J].
Barst, RJ ;
Rubin, LJ ;
Long, WA ;
McGoon, MD ;
Rich, S ;
Badesch, DB ;
Groves, BM ;
Tapson, VF ;
Bourge, RC ;
Brundage, BH ;
Koerner, SK ;
Langleben, D ;
Keller, CA ;
Murali, S ;
Uretsky, BF ;
Clayton, LM ;
Jobsis, MM ;
Blackburn, SD ;
Shortino, D ;
Crow, JW .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (05) :296-301
[4]  
BEGHETTI M, 1995, BRIT HEART J, V73, P65
[5]  
Clavecilla SQ, 2003, FORMULARY, V38, P150
[6]   Prevention of bacterial endocarditis - Recommendations by the American Heart Association [J].
Dajani, AS ;
Taubert, KA ;
Wilson, W ;
Bolger, AF ;
Bayer, A ;
Ferrieri, P ;
Gewitz, MH ;
Shulman, ST ;
Nouri, S ;
Newburger, JW ;
Hutto, C ;
Pallasch, TJ ;
Gage, TW ;
Levison, ME ;
Peter, G ;
Zuccaro, G .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1997, 277 (22) :1794-1801
[7]   B-type natriuretic peptide in cardiovascular disease [J].
de Lemos, JA ;
McGuire, DK ;
Drazner, MH .
LANCET, 2003, 362 (9380) :316-322
[8]   Intravenous nicardipine for treatment of severe hypertension in children [J].
Flynn, JT ;
Mottes, TA ;
Brophy, PD ;
Kershaw, DB ;
Smoyer, WE ;
Bunchman, TE .
JOURNAL OF PEDIATRICS, 2001, 139 (01) :38-43
[9]  
Gibbs JSR, 2001, HEART, V86, pI1
[10]  
GUNN VL, 2000, MOSBY YB, P575